title: [Long-term treatment with interferon-alpha can induce sarcoidosis. The connection can be stronger than earlier believed].
authors.affiliation: Institutionen für medicin, Solna, Karolinska Institutet. Johan.Grunewald@ki.se
authors.forename: Johan
authors.initials: J
authors.lastname: Grunewald
authors.forename: Olle
authors.initials: O
authors.lastname: Andersson
authors.forename: Mary
authors.initials: M
authors.lastname: Berlin
authors.forename: Maria
authors.initials: M
authors.lastname: Bradley
authors.forename: Göran
authors.initials: G
authors.lastname: Zetterberg
authors.forename: Ola
authors.initials: O
authors.lastname: Weiland
authors.forename: Anders
authors.initials: A
authors.lastname: Eklund
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008213:Lymphocyte Activation; D008262:Macrophage Activation; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000008:administration & dosage; D012307:Risk Factors; D012507:Sarcoidosis / Q000139:chemically induced* / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin